Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Symbole: 300357.SZ
SHZ
25.97
CNYPrix du marché aujourd'hui
44.2441
Ratio P/E
-6.3048
Ratio PEG
13.60B
Cap MRK
- 0.01%
Rendement DIV
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357-SZ) États financiers
Bilan
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1288.8 | 1135.7 | 1020.9 | |||||||||||||||
balance-sheet.row.short-term-investments | 0 | 117.4 | 295.1 | 370.9 | |||||||||||||||
balance-sheet.row.net-receivables | 0 | 214.9 | 284.9 | 256.2 | |||||||||||||||
balance-sheet.row.inventory | 0 | 59 | 48.4 | 53.8 | |||||||||||||||
balance-sheet.row.other-current-assets | 0 | 7.2 | 8.1 | 10.7 | |||||||||||||||
balance-sheet.row.total-current-assets | 0 | 1569.9 | 1477.1 | 1341.5 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 704.8 | 444.6 | 301.6 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 0 | 188.4 | 189.5 | 176.4 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 188.4 | 189.5 | 176.4 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | -43.2 | -216.7 | -287.6 | |||||||||||||||
balance-sheet.row.tax-assets | 0 | 5 | 4.9 | 5.8 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 137.2 | 298.4 | 394.3 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 992.3 | 720.7 | 590.5 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 0 | 2562.2 | 2197.9 | 1932 | |||||||||||||||
balance-sheet.row.account-payables | 0 | 8 | 7.7 | 5.1 | |||||||||||||||
balance-sheet.row.short-term-debt | 0 | 41.2 | 4 | 5.9 | |||||||||||||||
balance-sheet.row.tax-payables | 0 | 14.5 | 30.3 | 62.9 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 21.3 | 12.3 | 1.9 | |||||||||||||||
Deferred Revenue Non Current | 0 | 30.9 | 27.4 | 24.9 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 0 | 127.5 | 91.1 | 96.6 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 81.4 | 68 | 27.4 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 21.3 | 12.3 | 1.9 | |||||||||||||||
balance-sheet.row.total-liab | 0 | 258.5 | 170.8 | 135.4 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0 | 523.6 | 523.6 | 523.6 | |||||||||||||||
balance-sheet.row.retained-earnings | 0 | 1262.6 | 1092.7 | 889.6 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 270.7 | 235.1 | 194.7 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 128.2 | 128.2 | 128.2 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2185.1 | 1979.6 | 1736.1 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 2562.2 | 2197.9 | 1932 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 118.6 | 47.5 | 60.5 | |||||||||||||||
balance-sheet.row.total-equity | 0 | 2303.7 | 2027.1 | 1796.6 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||
Total Investments | 0 | 74.2 | 78.4 | 83.3 | |||||||||||||||
balance-sheet.row.total-debt | 0 | 62.4 | 16.3 | 7.8 | |||||||||||||||
balance-sheet.row.net-debt | 0 | -1108.9 | -824.4 | -642.2 |
Tableau des flux de trésorerie
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 295.5 | 335.7 | 326.3 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 38.5 | 26.1 | 25.1 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0.5 | -1 | |||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | -0.5 | 1 | |||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 47.4 | -47.2 | 11.5 | |||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | -30.9 | -34.6 | |||||||||||||||
cash-flows.row.inventory | 0 | -9.4 | 4.1 | -5.4 | |||||||||||||||
cash-flows.row.account-payables | 0 | 0 | -20.9 | 52.5 | |||||||||||||||
cash-flows.row.other-working-capital | 0 | 56.8 | 0.5 | -1 | |||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 0.7 | 45.7 | -2.3 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -209.2 | -188.7 | -122.2 | |||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0.2 | 0 | |||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -600.1 | -484.4 | -843.1 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 612.2 | 517.6 | 742.7 | |||||||||||||||
cash-flows.row.other-investing-activites | 0 | 5.1 | 37.1 | 10.2 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -191.9 | -118.2 | -212.3 | |||||||||||||||
cash-flows.row.debt-repayment | 0 | -20 | -5.8 | -5.8 | |||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | -105.6 | -105.2 | -83.8 | |||||||||||||||
cash-flows.row.other-financing-activites | 0 | 77.2 | 0 | 0 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -23.4 | -111 | -89.6 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 166.8 | 131.1 | 58.7 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 577.6 | 410.8 | 279.7 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 410.8 | 279.7 | 221 | |||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 382.1 | 360.3 | 360.6 | |||||||||||||||
cash-flows.row.capital-expenditure | 0 | -209.2 | -188.7 | -122.2 | |||||||||||||||
cash-flows.row.free-cash-flow | 0 | 172.9 | 171.5 | 238.4 |
Row du compte de résultat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 848.2 | 896 | 807.7 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 40.2 | 41.3 | 34.4 | |||||||||||||||
income-statement-row.row.gross-profit | 0 | 808 | 854.7 | 773.3 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0 | 1 | 16.1 | 28.5 | |||||||||||||||
income-statement-row.row.operating-expenses | 0 | 494.2 | 439.5 | 407.2 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 534.4 | 480.8 | 441.6 | |||||||||||||||
income-statement-row.row.interest-income | 0 | 31 | 24.8 | 22.6 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 1.3 | 0.4 | 0.4 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 1 | 2.5 | 0.1 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 1 | 16.1 | 28.5 | |||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 1 | 2.5 | 0.1 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 1.3 | 0.4 | 0.4 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 38.5 | 75.9 | 27.2 | |||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 0 | 345 | 396.2 | 392.9 | |||||||||||||||
income-statement-row.row.income-before-tax | 0 | 346 | 398.7 | 393 | |||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 50.4 | 63 | 66.7 | |||||||||||||||
income-statement-row.row.net-income | 0 | 310.2 | 348.8 | 338 |
Questions fréquemment posées
Quel est le total de Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) de l'actif total?
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) Le total des actifs est 2562166715.000.
Quel est le revenu annuel de l'entreprise?
Le revenu annuel est N/A.
Quelle est la marge bénéficiaire de l'entreprise?
La marge bénéficiaire de l'entreprise est 0.953.
Quel est le flux de trésorerie disponible de l'entreprise?
Le flux de trésorerie disponible est 0.312.
Quelle est la marge bénéficiaire nette de l'entreprise?
La marge bénéficiaire nette est 0.360.
Quel est le revenu total de l'entreprise?
Le revenu total est 0.392.
Qu'est-ce que Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) bénéfice net (revenu net)?
Le bénéfice net (revenu net) est 310184878.000.
Quel est l'endettement total de l'entreprise?
La dette totale est 62443059.000.
Quel est le montant des dépenses d'exploitation?
Les dépenses d'exploitation sont 494184515.000.
Quel est le montant de la trésorerie de l'entreprise?
Les liquidités de l'entreprise sont 0.000.